Tirzepatide Side Effects: What's Common, What's Serious, What Lasts
An evidence-based, plain-language guide to every side effect of tirzepatide — with real trial data, not marketing claims. Includes what to expect, what to ignore, and what to call your doctor about.
Roughly 80% of tirzepatide side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting. Most are mild to moderate, peak in the first 1–2 weeks after each dose increase, and resolve as your body adapts. Serious side effects are rare. The boxed warning concerns thyroid C-cell tumors observed only in rodents.
01 Common side effects of tirzepatide (with real rates)
The data below comes from SURMOUNT-1 (Jastreboff et al., NEJM 2022), the pivotal phase 3 trial that led to Zepbound's FDA approval for chronic weight management. Numbers reflect the percentage of trial participants who reported each side effect at least once during 72 weeks of treatment.
| Side effect | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 24% | 33% | 31% | 9% |
| Diarrhea | 19% | 21% | 23% | 7% |
| Constipation | 16% | 17% | 12% | 6% |
| Vomiting | 8% | 11% | 13% | 1% |
| Decreased appetite | 11% | 11% | 12% | 2% |
| Fatigue | 5% | 6% | 7% | 2% |
| Injection-site reaction | 5% | 5% | 5% | 1% |
| Hair loss / alopecia | 5% | 5% | 6% | 1% |
| Dyspepsia | 8% | 9% | 8% | 2% |
Source: SURMOUNT-1, n=2,539 adults with obesity or overweight. Rates rounded to nearest whole percent. Compounded tirzepatide is expected to have a similar profile because it contains the same active molecule.
02 The GI quartet: nausea, diarrhea, constipation, vomiting
These four account for most of what patients call "side effects." They are mediated by the drug's intended mechanism — GLP-1 slows gastric emptying and dampens hunger — so they're not random and they're not avoidable in their entirety. They are, however, almost always manageable.
Nausea
About 1 in 3 patients on tirzepatide will experience nausea at some point, usually concentrated in the first 1–2 weeks after starting and after each dose increase. It typically presents as a low-grade queasiness that worsens after large or fatty meals and improves with eating less. Severe nausea (vomiting, can't keep fluids down) is uncommon — about 5%.
What helps:
- Eat smaller, more frequent meals (4–6 small meals beats 3 large ones)
- Avoid fried, greasy, or rich foods for the first 2 weeks of each new dose
- Sip ginger tea or use real ginger candies
- Hydrate deliberately — dehydration worsens nausea
- Consider a 5–10 mg dose of vitamin B6 with each meal
- Inject in the evening if nausea is interfering with daytime activities
- Ondansetron (Zofran) 4 mg as needed if your prescriber agrees
Diarrhea
About 21% of patients report diarrhea — usually mild and self-limited. It tends to come and go, often correlating with fatty meals, dairy, or alcohol. Severe or bloody diarrhea is not typical of tirzepatide and warrants medical evaluation.
What helps:
- Hydrate aggressively — electrolyte solutions, not plain water
- Avoid trigger foods: dairy (if lactose-sensitive), alcohol, very fatty meals, sugar alcohols (sorbitol, xylitol, erythritol)
- Soluble fiber (psyllium) often helps both diarrhea and constipation
- Consider probiotics
- Loperamide (Imodium) for occasional flares — not daily
Constipation
Sounds paradoxical alongside diarrhea, but constipation is actually more common in some patients (17%). The mechanism is also slowed GI transit. The two camps tend to be distinct — most patients are either "the diarrhea type" or "the constipation type," not both.
What helps:
- Increase water intake to 80+ oz/day
- Add 25+ g of soluble + insoluble fiber daily (psyllium, chia, ground flax)
- Magnesium citrate 200–400 mg at bedtime
- Daily walking (movement helps motility)
- Avoid loperamide; consider polyethylene glycol (MiraLAX) for stubborn cases
Vomiting
Vomiting is less common than nausea (8–13%) and almost always concentrated in the first week of a new dose, especially when titrating to 7.5 mg or higher. If you're vomiting more than once daily for more than 48 hours, or you can't keep fluids down, contact your prescriber. Severe persistent vomiting can cause dehydration and acute kidney injury — this is a real, documented risk and is the most common reason for ER visits related to tirzepatide.
03 Tirzepatide and hair loss: real or rumor?
Hair loss is one of the most-Googled tirzepatide concerns. Trial data shows it's real but uncommon: about 5–6% of tirzepatide patients reported hair loss vs. 1% on placebo in SURMOUNT-1. The mechanism, however, is not the drug — it's the rate of weight loss.
The medical name is telogen effluvium: a temporary shedding triggered when a large fraction of hair follicles enter the resting phase simultaneously due to physiological stress. It can be triggered by surgery, childbirth, severe illness, crash dieting, iron deficiency, thyroid changes — and yes, by losing 15%+ of body weight in a few months.
The good news
- It's temporary and reversible. Hair regrows once your weight stabilizes.
- It typically peaks 3–4 months after the steepest weight-loss phase.
- Full regrowth usually completes within 6–9 months of stabilization.
- Hair density returns; the actual follicles are not destroyed.
How to minimize it
- Protein — at least 0.6–0.8 g per pound of goal body weight per day. Most under-eat protein on GLP-1s.
- Don't go below ~1,200 kcal/day. The temptation to eat less because you're not hungry is strong. Resist it.
- Iron / ferritin — if you're female and pre-menopausal, get ferritin checked. Low ferritin (<50) accelerates hair shedding.
- Vitamin D — get a level. Supplement if <30 ng/mL.
- Biotin, zinc, and B-complex — modest evidence, low risk.
- Avoid harsh chemical treatments (bleach, relaxers) during peak shedding.
04 Fatigue, headache, and sleep changes
Fatigue is reported by about 5–7% of patients. It is almost always caused by under-eating. When tirzepatide kills your appetite and you start eating 800 kcal a day without realizing it, your body responds with the predictable signs of energy deficit: tired, cold, mentally foggy, hair shedding, irritable.
The fix is rarely to lower the dose. The fix is usually to eat on a schedule rather than waiting for hunger, and to track protein and total calories for a week or two until you have a baseline. A well-fueled patient on 15 mg tirzepatide should not feel exhausted.
Headache
About 6% of patients report headache, often mild and concentrated in the first week. The leading culprit is dehydration — between GI side effects and reduced appetite (and reduced thirst with reduced appetite), water intake quietly drops. Aim for 80+ oz/day. Caffeine withdrawal also matters if your coffee intake drops alongside your appetite.
Sleep
Most patients sleep better on tirzepatide because weight loss improves obstructive sleep apnea, snoring, GERD, and night-time blood-sugar excursions. Some report initial sleep disruption from injection-site discomfort or transient anxiety in the first weeks. Severe insomnia is not characteristic of tirzepatide.
05 Serious and rare side effects
These are uncommon but worth knowing. The threshold for contacting your prescriber should be low for any of the symptoms below.
Pancreatitis
Acute pancreatitis was reported in about 0.2–0.4% of trial patients — slightly higher than placebo but a small absolute number. Symptoms: severe upper abdominal pain that radiates to the back, nausea/vomiting that doesn't improve, fever. This is an ER visit, not a "wait and see." Tirzepatide should be permanently discontinued if pancreatitis is confirmed.
Gallbladder problems
Rapid weight loss (from any cause) increases the risk of gallstones and acute cholecystitis. GLP-1 medications appear to increase this baseline risk modestly. Symptoms: right upper abdominal pain (often after fatty meals), shoulder-blade pain, fever, jaundice.
Thyroid C-cell tumors (boxed warning)
In 2-year rodent studies, tirzepatide caused thyroid C-cell tumors in rats. Whether this matters in humans is unknown — human C-cells are far less dense and the rodent finding has not reproduced in epidemiological data with related drugs. The FDA mandates a boxed warning regardless. Tirzepatide is contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2).
Hypoglycemia
Tirzepatide alone does not cause hypoglycemia in non-diabetic patients (it stimulates insulin only when blood sugar is high). If you also take insulin or a sulfonylurea, your dose of those drugs may need to be reduced.
Allergic reactions
Severe allergic reactions are rare but reported. Symptoms: rash, itching, swelling (especially of face/throat), difficulty breathing. Discontinue and seek medical attention immediately.
Diabetic retinopathy
Patients with pre-existing diabetic retinopathy (background or proliferative) may experience worsening with rapid blood-sugar improvement on any GLP-1. If you have known diabetic retinopathy, get baseline ophthalmology before starting and follow up at 6 months.
Acute kidney injury
Almost always secondary to severe dehydration from vomiting/diarrhea, not the drug directly. Symptoms: decreased urination, dark urine, swelling, confusion. Stay hydrated; if you can't, get IV fluids.
06 Long-term side effects: what we know in 2026
The longest published tirzepatide data is approximately 3 years (combining SURMOUNT-1 extension, SURMOUNT-4, and ongoing diabetes follow-ups). At the 3-year mark, the safety profile is consistent with what was seen in 1- and 2-year trials. There are no emerging signals for cancer, cardiovascular harm, dementia, kidney dysfunction, or organ toxicity in the published data.
Concerns that have not materialized:
- No increase in pancreatic cancer (large meta-analyses of GLP-1 data)
- No increase in suicidal ideation (FDA review, 2024)
- No clinically meaningful loss of bone density when adequate protein is maintained
- No "metabolic damage" or permanent metabolic suppression
Concerns that are real with extended use:
- Muscle loss with weight loss. Roughly 25–40% of total weight lost is lean mass unless you're actively resistance-training and eating high protein. This isn't unique to tirzepatide — it happens with any large caloric deficit.
- Weight regain on discontinuation. SURMOUNT-4 showed a 14% body-weight regain over 52 weeks after stopping the drug. This is biology, not failure: tirzepatide is treatment, not cure.
- Possible accelerated facial volume loss ("Ozempic face") — driven by weight loss, not the drug itself, and also reversible with weight stabilization.
07 Drug interactions and alcohol
Drug interactions
Tirzepatide has relatively few clinically significant interactions because it's not metabolized through the CYP450 system. The two real interactions to know:
- Insulin / sulfonylureas — increased hypoglycemia risk; doses should be reduced when starting tirzepatide in diabetics.
- Oral contraceptives — slowed gastric emptying may reduce absorption of oral contraceptives, especially right after starting and after dose escalations. Use a barrier method or non-oral contraception for 4 weeks after starting and after each dose increase.
Alcohol
No formal drug interaction, but most patients report dramatically reduced alcohol tolerance and consumption. This isn't accidental — GLP-1 receptors in the brain's reward system modulate alcohol craving. Researchers are actively studying tirzepatide and semaglutide for alcohol use disorder. Practical implications: expect a much smaller "stop point," worse hangovers, and potentially worse next-day GI symptoms.
08 The first-30-days survival kit
A practical checklist for the first month on tirzepatide. Most side effects appear here, and most can be prevented or minimized with the right preparation.
Eat & drink
- Smaller portions, 4–6 times daily
- Protein first, every meal (target 0.6 g/lb)
- 80+ oz water/day
- Skip fried, greasy, very rich meals weeks 1–2
- No alcohol the first 2 weeks
Stock the cabinet
- Electrolyte powder (LMNT, Liquid IV)
- Ginger tea or candies
- Psyllium husk fiber
- Magnesium citrate (for constipation)
- Tylenol or Advil for headaches
- Loperamide (occasional diarrhea use)
Inject smart
- Same day each week, ±24h
- Rotate sites: stomach, thigh, upper arm
- Inject in the evening if nausea hits next day
- Room-temp drug stings less than cold
Call the doctor if…
- Severe abdominal pain radiating to back
- Vomiting > 48h, can't hydrate
- Yellow skin or eyes
- Rash, swelling, breathing difficulty
- Severe headache or vision changes
Get tirzepatide with provider support included.
The right telehealth provider doesn't just send you a vial — they answer side-effect questions, help titrate, and adjust your dose. See our top-rated picks.
See Top Providers→09 Tirzepatide side effects FAQ
Gastrointestinal symptoms dominate the side effect profile: nausea (28%), diarrhea (21%), constipation (17%), vomiting (13%), and dyspepsia (9%). Most are mild to moderate, peak after each dose increase, and improve within 1–2 weeks of dose stability. Less commonly reported are fatigue, hair loss, injection-site reactions, and headache.
Yes, but the mechanism is almost certainly rapid weight loss, not the drug itself. In SURMOUNT-1, hair loss was reported in 4–6% of tirzepatide patients vs. 1% on placebo. The medical term is telogen effluvium — a temporary shedding triggered by any major weight loss, calorie restriction, or physiological stress. It typically peaks 3–4 months after losing significant weight and resolves within 6–9 months as the body stabilizes.
Fatigue is reported by about 5–7% of trial patients, vs 2% on placebo. The cause is rarely the drug pharmacologically — it's the side effect of eating dramatically less. Caloric deficits below ~1,200 kcal/day, combined with poor protein intake, dehydration, and electrolyte loss from GI symptoms, cause the bulk of the fatigue. Most patients feel better within 2–4 weeks once eating patterns normalize.
No — telogen effluvium from rapid weight loss is reversible. Hair shedding peaks 3–4 months after the steepest weight-loss phase and regrows over the following 6–9 months. To minimize it: eat enough protein (≥0.6 g/lb of goal body weight), don't drop calories below 1,200/day, supplement iron and ferritin if low, and consider a 5,000 IU vitamin D + biotin combination if your dermatologist agrees.
There is no proven causal link between tirzepatide and clinical depression or anxiety. The FDA monitored these signals after early reports about semaglutide and found no increase in suicidal ideation in randomized trial data. That said, some patients report mood changes — usually transient and tied to GI symptoms, sleep disruption, or the psychological adjustment to dramatic appetite changes. If you have a history of mood disorders, mention it to your prescriber.
The longest published data is roughly 3 years (SURMOUNT-4 extension and ongoing diabetes follow-ups). At that point, the safety profile remains consistent with shorter trials — predominantly GI, with no emerging signals for cancer, cardiovascular harm, or organ toxicity. Theoretical concerns from rodent studies (thyroid C-cell tumors) have not materialized in human data. Post-marketing surveillance is ongoing through the FDA Adverse Event Reporting System.
There is a boxed warning for thyroid C-cell tumors based on rodent studies, but no proven human risk. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). For everyone else, current evidence does not support an increased cancer risk with GLP-1 or GLP-1/GIP therapy.
There's no direct dangerous interaction, but alcohol on tirzepatide is often unpleasant. Many patients report dramatically lower alcohol tolerance, faster onset of nausea, and worse hangovers. The drug also slows gastric emptying, so alcohol absorption is altered. Most people end up drinking far less without consciously trying — a known side effect that's actually proving therapeutically interesting in alcohol use disorder research.
GLP-1 and GIP signaling speed up some parts of the GI tract while slowing others. The result for many patients is altered transit time — sometimes manifesting as loose stools, especially in the first 1–2 weeks of a new dose. It usually resolves on its own. If diarrhea is severe or persistent more than a week, or if you're also vomiting and can't stay hydrated, contact your prescriber.
Severe abdominal pain (especially radiating to the back) — possible pancreatitis. Yellow skin or eyes — possible gallbladder or liver problem. Severe persistent vomiting with inability to keep fluids down — risk of dehydration and acute kidney injury. Allergic reaction (swelling, rash, difficulty breathing). Dark urine or muscle pain — rare rhabdomyolysis. Any of these warrant prompt medical attention, not waiting for the next telehealth visit.
Related guides
Dosing & calculator →
Slow titration is the #1 way to reduce side effects. Get the schedule.
Diet & lifestyle →
What to eat (and avoid) to minimize GI symptoms.
Realistic results →
Month-by-month timelines and what's normal vs not.